Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-negative Breast Cancer × trastuzumab deruxtecan × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 62 Neoplasm Metastasis 10 Brain Neoplasms 7 Triple Negative Breast Neoplasms 5 Stomach Neoplasms 3 Colorectal Neoplasms 3 Neoplasms 2 HER2-positive Breast Cancer 2 Carcinoma, Non-Small-Cell Lung 2 Breast Cancer With Brain Metastasis 2 Advanced Breast Cancer 2 Salivary Gland Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasm, Residual 1 Meningeal Carcinomatosis 1 HER2-negative Breast Cancer 1 HER2-low Hormone Receptor Positive Breast Cancer 1 HER2-Positive Primary Breast Cancer 1 HER2 Overexpression 1 Glioma 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Colonic Neoplasms 1 Carcinosarcoma 1 Carcinoma, Transitional Cell 1 Breast Cancer Metastatic 1 Astrocytoma 1 Adenocarcinoma Of Esophagus 1

Interventions

eribulin 2 Vinorelbine 2 Paclitaxel 2 Cyclophosphamide 2 trastuzumab deruxtecan 1 taxane 1 sacituzumab govitecan 1 pembrolizumab 1 pamiparib 1 liposomal doxorubicin 1 camrelizumab 1 Precision Medicine 1 Gemcitabine 1 Epirubicin 1 Doxorubicin 1 Docetaxel 1 Cisplatin 1 Carboplatin 1 Capecitabine 1 Anthracyclines 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06102824 2024-11-25

ORIENTA

Guangdong Provincial People's Hospital

Phase 2 Recruiting

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡